The company pled guilty to one misdemeanor charge and paid a fine of $15 million. As a result, the department of justice dismissed 13 felony charges against the company. The company was charged with marketing unapproved products for human bone growth, according to Bloomberg Businessweek news report.
Stryker’s misbrand may have led surgeons to combine the company’s OP-1 and OP-1 Putty with bone filler Calstrux, which could have adverse events.
Related Articles on Orthopedic Devices:
Zyga Technology Names Jim Bullock President & CEO
Zimmer Acquires Synvasive Technology
VG Innovations Releases Spine Device for Low Back Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.